Chongkundang Bio Holds First Anniversary Symposium for Botulinum Toxin "Tmbus Injection"

Chongkundang Bio held a symposium in celebration of the first anniversary of the launch of its botulinum toxin product, Tmbus Injection, inviting leading domestic cosmetic surgery professionals.

Chongkundang Bio announced on the 13th that it had hosted the symposium on the 11th at Chosun Palace Gangnam in Seoul. The event, themed "A New Standard for Safe Toxin Procedures and Product Selection," served as a platform to share clinical experiences accumulated during the year since Tmbus Injection’s launch, as well as the latest procedural trends.

On the 11th, at the one-year anniversary symposium of the botulinum toxin "Tmbus Injection" held at Chosun Palace Gangnam in Seoul, Baek Kyungtae, director of It's Me Clinic Sejong Branch, is giving a lecture. Chongkundang Bio

Tmbus Injection is a new strain toxin produced with an exclusive strain from a German institute. Its key features include a formulation free of human serum albumin (HSA-Free), the inclusion of L-histidine, and Halal certification. The company explained that these differentiating factors are helping it expand its presence in the premium botulinum toxin market.

In the first session, Iksoo Ko, Director of Ko Iksoo Plastic Surgery, delivered a lecture outlining safe administration techniques for botulinum toxin and criteria for product selection. Director Ko stated, "As the domestic botulinum toxin market matures, both medical professionals and patients are placing greater emphasis on safety and transparency in product selection," and added, "Tmbus Injection meets all these market demands through its HSA-Free formulation, exclusive German strain, and Halal certification." He further explained, "Thanks to the inclusion of L-histidine, the product offers antioxidant effects, making it well-suited for premium procedures that go beyond simple wrinkle improvement to also address skin health."

Next, Baek Kyung-Tae, Director of It's Me Clinic Sejong Branch, shared his clinical experience and procedural insights from using Tmbus Injection over the past year. The final session featured Park Shin-Hye, Director of Miho Clinic, who introduced a range of cases involving combined procedures using Tmbus Injection.

During the event, the upcoming "Tmbus Injection 200 Units" product, scheduled for release in early August, was also introduced. Following the existing 100-unit product, the 200-unit version is expected to provide a more efficient option for broad-area or high-volume procedures.

Wankap Park, CEO of Chongkundang Bio, remarked, "Marking the first anniversary of Tmbus Injection, it is meaningful to share clinical experience and expertise built together with key doctors in Korea," and added, "We will leverage the unique differentiating features of Tmbus Injection as a competitive advantage to further expand our presence in the botulinum toxin market both domestically and globally."

This content was produced with the assistance of AI translation services.